REASON: Factors influencing outcome in patients (pts) with NSCLC stage IIIB/IV and mutated EGF receptor (EGFR-M+) treated with gefitinib.

7. Juni 2016

Schuette, W., Eberhardt, W., Schirmacher, P., Dietel, M., Zirrgiebel, U., Radke, S., Thomas, M., 2016.

Oncol Res Treat, 39 (suppl 1) (ID 0345), 120. doi:10.1159/000444354